Table 2.
Risk factor definitions in Hodgkin’s lymphoma. Patients in CS I–II are staged unfavorable if at least one of the listed risk factors is present [34].
| Risk Factors | GHSG | EORTC | NCIC/ECOG | NCCN |
|---|---|---|---|---|
| Large mediastinal mass | Yes 1, ratio ≥ 1/3 | Yes, ratio ≥ 0.35 | No | Yes, ratio > 1/3 |
| Extranodal disease | Yes 1 | No | No | Yes |
| Nodal areas | Yes, ≥3 areas | Yes, ≥4 areas | Yes, ≥4 areas | Yes, ≥3 regions |
| ESR | Yes, ≥50 (A) or ≥30 (B) | Yes, ≥50 (A) or ≥30 (B) | Yes, ≥50 | Yes, ≥50 (A) |
| B-symptoms | No | No | No | Yes |
| Bulk | No | No | No | Yes, >10 cm |
| Age | No | Yes, ≥50 years | Yes, ≥40 years | No |
| Histology other than LP/NS | No | No | Yes | No |
Abbreviations: CS clinical stage, ESR erythrocyte sedimentation rate, A without B-symptoms, B with B-symptoms, LP lymphocyte predominant, NS nodular sclerosis, GHSG German Hodgkin Study Group, EORTC European Organization for Research and Treatment of Cancer, NCIC National Cancer. Institute of Canada, ECOG Eastern Cooperative Oncology Group, NCCN National Comprehensive Cancer Network. 1 According to GHSG, patients with CSIIB and a large mediastinal mass or extranodal disease are considered as advanced stage.